BridgeMD
CLEAR-PATH trial
EU CTIS ID: 2024-513363-15-01
What this study is testing
To assess whether and to what extent DAPT is superior to SAPT, in reducing the combined endpoint of all-cause death, MACE and MALE within one-year follow-up in PAD patients who underwent EVR.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Lesions of the iliac, femoropopliteal, and/or below-the-knee (BTK) arteries;
- At least one TASC lesion;
- Rutherford (1-6) classes with an indication for an endovascular intervention
- Proficient understanding of the consequences of enrolment by the patient
- Written informed consent by the patient;
- Age ≥ 45 years
You likely can't join if
- Acute (limb) ischemia
- Patients who are pregnant/contemplating pregnancy/nursing.
- Patients requiring dialysis
- Patients with liver failure and at least one of the following criteria; 1. elevated INR value, or; 2. portal hypertension, or; 3. thrombocytopenia <50x10^9/L, or; 4. INR, portal tension, or platelet count are unknown.
- Reported intolerance or hypersensitivity to the study medications
- Use of anticoagulant therapy (DOACs or coumarin)
See the full eligibility criteria
- Lesions of the iliac, femoropopliteal, and/or below-the-knee (BTK) arteries;
- At least one TASC lesion;
- Rutherford (1-6) classes with an indication for an endovascular intervention
- Proficient understanding of the consequences of enrolment by the patient
- Written informed consent by the patient;
- Age ≥ 45 years
- And eligibility of lesions for; 1. Percutaneous transluminal angioplasty (PTA) or recanalization with or without additional stenting based on prevailing guidelines, or; 2. Hybrid procedure with an endarterectomy of the common femoral artery and additional iliac, femoral or tibial PTA, or; 3. A reintervention within 2 months due to a phased treatment.
- Acute (limb) ischemia
- Patients who are pregnant/contemplating pregnancy/nursing.
- Patients requiring dialysis
- Patients with liver failure and at least one of the following criteria; 1. elevated INR value, or; 2. portal hypertension, or; 3. thrombocytopenia <50x10^9/L, or; 4. INR, portal tension, or platelet count are unknown.
- Reported intolerance or hypersensitivity to the study medications
- Use of anticoagulant therapy (DOACs or coumarin)
- Use of non-steroidal anti-inflammatory drugs >2 weeks which cannot be discontinued
- Patients incompetent of understanding the consequences of enrolment in the trial
- Patients with a reintervention due to restenosis/reocclusion within 2 months
- Patients with a hybrid procedure other than endarterectomy of the common femoral artery such as femoral bypass
- Patients with coagulopathy
- Patients with a peptic ulcer confirmed by an esophagogastroduodenoscopy in their medical history
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.